Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
- 1Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
- 2Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China
A Corrigendum on
Controlling nutritional status (CONUT) predicts survival ingastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1)outcomes
by Chen L, Sun H, Zhao R, Huang R, Pan H, Zuo Y, Zhang L, Xue Y, Li X and Song H (2022). Front. Pharmacol. 13:836958. doi: 10.3389/fphar.2022.836958
In the published article, there was an error in the Author list and Correspondence section, and authors Hongjiang Song and Xingrui Li were inserted in the wrong order. The corrected Author list and Correspondence section appear below.
“Li Chen, Hao Sun, Ruihu Zhao, Rong Huang, Hongming Pan, Yanjiao Zuo, Lele Zhang, Yingwei Xue, Hongjiang Song and Xingrui Li.”
“*Correspondence: Hongjiang Song, hongjiangsong2016@163.com; Xingrui Li, lixingrui@tjh.tjmu.edu.cn.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: gastric cancer, controlling nutritional status, immune checkpoint inhibitors, PD-1, PD-L1
Citation: Chen L, Sun H, Zhao R, Huang R, Pan H, Zuo Y, Zhang L, Xue Y, Song H and Li X (2022) Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes. Front. Pharmacol. 13:1079635. doi: 10.3389/fphar.2022.1079635
Received: 25 October 2022; Accepted: 26 October 2022;
Published: 14 November 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Chen, Sun, Zhao, Huang, Pan, Zuo, Zhang, Xue, Song and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hongjiang Song, hongjiangsong2016@163.com; Xingrui Li, lixingrui@tjh.tjmu.edu.cn
†ORCID: Li Chen, 0000-0002-6989-1177
‡These authors have contributed equally to this work